



Exelixis Announces December 1 Webcast of Presentation at Piper Jaffray's 21st Annual Healthcare Conference

November 25, 2009

SOUTH SAN FRANCISCO, Calif., Nov 25, 2009 (BUSINESS WIRE) -- Exelixis, Inc. (NASDAQ:EXEL) announced today that Charles Butler, the company's vice president, investor relations and corporate communications, will present at Piper Jaffray's 21st Annual Healthcare Conference at 1:30 p.m. EST / 10:30 a.m. PST on Tuesday December 1, 2009 in New York. Mr. Butler will discuss the company's corporate strategy, financial outlook and development pipeline.

The event will be webcast and may be accessed in the Event Calendar page under Investors at <http://www.exelixis.com>.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech, Boehringer Ingelheim, Wyeth Pharmaceuticals (acquired by Pfizer Inc.), and Daiichi-Sankyo. For more information, please visit the company's web site at <http://www.exelixis.com>.

Exelixis and the Exelixis logo are registered U.S. trademarks.



SOURCE: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor Relations
and Corporate Communications
cbutler@exelixis.com
DeDe Sheel, 650-837-8231
Associate Director,
Investor Relations
dsheel@exelixis.com